Drug intelligence / Profile preview

thioraviroc

Development stage: Phase 1
Lead developer: Shanghai Institute of Materia Medica
Modality: Small Molecules
Administration: Oral

Overview

Thioraviroc is a small molecule CCR5 antagonist developed by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, for the treatment of HIV-1 infection. It is a sulfur-containing analog of maraviroc, specifically designed to inhibit the entry of R5-tropic HIV-1 strains into host cells. By binding to the CCR5 coreceptor on the surface of CD4+ T lymphocytes, thioraviroc prevents the viral envelope glycoprotein gp120 from binding, which is a critical step for viral fusion and entry. Preclinical and clinical studies in China have indicated that thioraviroc possesses potent antiviral activity and a favorable safety profile, positioning it as a potential therapeutic option for patients with CCR5-tropic HIV-1.

Other names: thio-maraviroc

Targets

CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on thioraviroc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thioraviroc.